Walter Blättler
Presidente en Formation Biologics Corp. .
Cargos activos de Walter Blättler
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Formation Biologics Corp.
Formation Biologics Corp. Miscellaneous Commercial ServicesCommercial Services Formation Biologics Corp. operates as a biopharmaceutical drug development company. It discovers and develops drugs and medicines for treatment of patients with cancers and orphan diseases. The company was founded in 2011 and is headquartered in Austin, TX. | Presidente | - | - |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | Presidente | - | - |
Historial de carrera de Walter Blättler
Antiguos cargos conocidos de Walter Blättler.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Bristol-Myers Squibb FCT bêta, Inc.
Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada. | Director/Miembro de la Junta | 11/11/2014 | 21/09/2020 |
MORPHOSYS AG | Director/Miembro de la Junta | 19/05/2010 | 08/05/2015 |
Independent Dir/Board Member | 01/01/2007 | 08/05/2015 | |
CoStim Pharmaceuticals, Inc.
CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2012 | 01/01/2014 |
Proterris (Portugal) - Investigação e Desenvolvimento
Proterris (Portugal) - Investigação e Desenvolvimento Pharmaceuticals: GenericHealth Technology Proterris (Portugal) - Investigação e Desenvolvimento de Produtos Farmacêuticos, Sociedade Unipessoal Lda. develops Carbon Monoxide-Releasing Molecules (CORMs) for therepy. The company was founded by Carlos José Rodrigues Crispim Romão, Werner Ernest Hass, Nuno Manuel de Castro Santos Arante e Oliveira and Stan Kugell on January 4, 2002 and is headquartered in Oeiras, Portugal. | Corporate Officer/Principal | 09/09/2009 | 01/01/2011 |
IMMUNOGEN, INC. | Corporate Officer/Principal | 05/03/2007 | 05/03/2007 |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Fundador | 01/01/2015 | - |
Corporate Officer/Principal | 01/01/2015 | - |
Formación de Walter Blättler.
Swiss Federal Institute of Technology | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Canadá | 3 |
Portugal | 2 |
Operativa
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Chairman | 2 |
Sectorial
Health Technology | 8 |
Consumer Services | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MORPHOSYS AG | Health Technology |
Empresas privadas | 7 |
---|---|
Proterris (Portugal) - Investigação e Desenvolvimento
Proterris (Portugal) - Investigação e Desenvolvimento Pharmaceuticals: GenericHealth Technology Proterris (Portugal) - Investigação e Desenvolvimento de Produtos Farmacêuticos, Sociedade Unipessoal Lda. develops Carbon Monoxide-Releasing Molecules (CORMs) for therepy. The company was founded by Carlos José Rodrigues Crispim Romão, Werner Ernest Hass, Nuno Manuel de Castro Santos Arante e Oliveira and Stan Kugell on January 4, 2002 and is headquartered in Oeiras, Portugal. | Health Technology |
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
CoStim Pharmaceuticals, Inc.
CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA. | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Bristol-Myers Squibb FCT bêta, Inc.
Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada. | Health Technology |
Formation Biologics Corp.
Formation Biologics Corp. Miscellaneous Commercial ServicesCommercial Services Formation Biologics Corp. operates as a biopharmaceutical drug development company. It discovers and develops drugs and medicines for treatment of patients with cancers and orphan diseases. The company was founded in 2011 and is headquartered in Austin, TX. | Commercial Services |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | Health Technology |
- Bolsa de valores
- Insiders
- Walter Blättler
- Experiencia